内容摘要：recommends for people with high blood pressure or other heart disease risk factors, coconut aminos are certainly a better choice. Even if you don’t keep a close eye on your sodium intake, opting for coconut aminos can make it much easier to stay below the USDA

recommends for people with high blood pressure or other heart disease risk factors, coconut aminos are certainly a better choice. Even if you don’t keep a close eye on your sodium intake, opting for coconut aminos can make it much easier to stay below the USDA

When staff tested the tool Monday with questions about FDA-approved products or other public information, it provided summaries that were either incorrect or only partially accurate, one of the people said.It’s unclear, the people said, whether CDRH-GPT will eventually be integrated into Elsa or remain a standalone system.

Richard Painter, a law professor at the University of Minnesota and a former government ethics lawyer, said there are also concerns about potential conflicts of interest. He wondered whether there is a protocol in place to prevent any government official — such as an FDA reviewer using the technology — from having financial ties with companies that could benefit from AI. While the technology has existed for years, he said, it‘s still a new venture for the FDA.“We need to make sure that the people involved in these decisions do not have a financial interest in the artificial intelligence companies that would get the contracts,” Painter said. “A conflict of interest can greatly compromise the integrity and the reputation of a federal agency.”Some at the FDA don’t see AI as a solution to their overwhelming workloads — they see it as a sign that they may eventually be replaced.

The FDA is “already spread thin from the RIF [layoffs] and the steady loss of individuals while in a hiring freeze and no capacity to backfill,” one of the people said.The U.S. Food and Drug Administration (FDA) has approved the first artificial intelligence (AI) tool to predict

The authorization was confirmed by digital health tech company Clairity, the developer of Clairity Breast – a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram.

In a press release, Clairity shared its plans to launch theWith these tools and approaches, workplaces can become more inclusive. Employers won’t just help people with dementia—they’ll also benefit from retaining skilled, experienced workers.

One of the biggest misunderstandings about dementia is that it only affects older adults. This isn’t true. Around 9% of the world’s 35.6 million people living with dementia are under 65. That’s roughly 370,000 new cases of young onset dementia each year. Some people are diagnosed in their 40s or 50s—well before retirement age.Still, most policies and research ignore this group. The focus stays on older populations, leaving younger workers with dementia out of the picture. That has real consequences. Without support, many leave the workforce too early.

Like these kind of stories? Get“The reality is, this is not dealt with in any meaningful way right now—there are very rarely strategies in place,” says Fletcher. He hopes the UK government’s recent plans to encourage more